Brixton Biosciences raised $33M in a Series B funding to advance its Neural Ice™ technology for the treatment of pain
Amount Raised
$33 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareInvestors
Description
Brixton Biosciences, a spin-out from Massachusetts General Brigham, closed a Series B funding round of $33M led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures, PV Capital Management, and Catalyst Health Ventures. The funding will be used to initiate pivotal clinical studies for chronic and acute pain indications and to expand the applicability of its Neural Ice™ platform.
Quick answer
Brixton Biosciences raised $33 Million in a Series B round, dated May 14, 2024. Investors: Catalyst Health Ventures, PV Capital Management, Excelestar Ventures, Sparta Group, SV Health Investors and Schooner Capital. Brixton Biosciences is based in Cambridge, Massachusetts, United States.
- How much did Brixton Biosciences raise?
- Brixton Biosciences raised $33 Million in a Series B round on May 14, 2024.
- Who invested in Brixton Biosciences?
- Catalyst Health Ventures, PV Capital Management, Excelestar Ventures, Sparta Group, SV Health Investors and Schooner Capital are named as investors in this round.
- What does Brixton Biosciences do?
- Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain.
- Where is Brixton Biosciences based and how big is it?
- Brixton Biosciences is based in Cambridge, Massachusetts, United States. Fundz records about 28 employees.
- Who are the decision-makers at Brixton Biosciences?
- Fundz holds 1 contact at Brixton Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Brixton Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Phlow raised $5M on June 28, 2024.
- NewcelX raised $787K on June 28, 2024.
- Waypoint Bio raised $15M (Seed) on June 28, 2024.
- DiaMedica Therapeutics raised $12M on June 28, 2024.
- Route 92 Medical raised $50M on June 28, 2024.
- LifeLens Technologies raised $18M on June 28, 2024.
Who to call at Brixton Biosciences, and when
A new round usually means Brixton Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Brixton Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Brixton Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Brixton Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Brixton Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansBrixton Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.